Insights Into Breast Cancer

Perspectives on current treatment practices regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer (TNBC), and attitudes toward recently introduced and upcoming agents in relapsed/refractory disease

Florida – February 10, 2024

Faculty Chair

Reshma Mahtani, DO

Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA

Southwest – February 24, 2024

Faculty Chair

Jason Mouabbi, MD

MD Anderson Cancer Center, Houston, TX, USA

Southeast – March 16, 2024

Faculty Chair

Philip Lammers, MD

Baptist Cancer Center, Bartlett, TN, USA

Central – April 20, 2024

Faculty Chair

TBC

TBC

Northeast – August 2024

Faculty Chair

TBC

TBC

Midwest – September 2024

Faculty Chair

TBC

TBC

California – October 2024

Faculty Chair

TBC

TBC

Northwest – November 2024

Faculty Chair

TBC

TBC

More Information

  • Tampa, FL
  • Florida

More Information

  • Scottsdale, AZ
  • Arizona, Colorado, Nevada, New Mexico, Southern California, Utah

More Information

  • Atlanta, GA
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia

More Information

  • Dallas, TX
  • Arkansas, Kansas, Louisiana, Missouri, Oklahoma, Texas

More Information

  • Philadelphia, PA
  • Connecticut, Delaware, District of Columbia, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont

More Information

  • Chicago, IL
  • Illinois, Indiana, Iowa, Michigan, Minnesota, Nebraska, North Dakota, Ohio, South Dakota, Wisconsin

More Information

  • San Diego, CA
  • California

More Information

  • Seattle, WA
  • Idaho, Montana, Northern California, Oregon, Washington, Wyoming

Example Agenda

Download the meeting agenda

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A moderated roundtable discussion focusing on the treatment of breast cancer
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies will be obtained
    • HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, and chemotherapies
    • HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, trastuzumab deruxtecan, tucatinib, neratinib, AIs, and chemotherapies
    • TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan), immunotherapy, and chemotherapies

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprises 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.